Vitamin D in Multiple Sclerosis
Brief description of study
The purpose of this study is to determine if giving a higher dose of vitamin D3 results in lower risk of MS attacks or worsening.
Detailed description of study
Eligible participants include relapsing remitting multiple sclerosis patients that are willing to start daily administration of glatiramer acetate (also known as Copaxone) for the study. Participants will also take a daily high or low dose of vitamin D3 as an add-on therapy,
Patients that have already started copaxone may also be eligible to participate if they have not been on copaxone for more than 90 days.
Participants will complete study related and safety assessments over a two year period.
Both the Copaxone and Vitamin D will be provided to particpants free of charge through the study.
* Please note, patients must also be able to walk 500 meters (1640 feet) without rest or assistance.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Multiple sclerosis, RRMS, Relapsing-Remitting Multiple Sclerosis
-
Age: Between 18 Years - 50 Years
-
Gender: All
Updated on
01 May 2019.
Study ID: 815804
